We analyse the following segments: non-prescription and prescription drugs, parapharmaceuticals, private and public healthcare and medical devices. Our market reports are prepared by recognized pharma and healthcare industry analysts well-versed in the workings of the market and quoted often in the Polish and foreign media.
We provide accurate, comparative data and information describing market value and growth (historical and projected), along with descriptions of influential trends and events influencing the market, detailed analyses of the pharma and healthcare market segments (including forecasts), as well as discussion of the shares and strategies of key players.
Over the years, PMR has formed partnerships with key market players, assisting companies in the development, implementation and monitoring of successful market strategies. Our in-depth analyses also aid players in developing expansion plans into additional new markets such as CIS countries.
According to PMR data, in 2017, the OTC market in Poland (pharmacy and non-pharmacy sales,
OTC drugs and dietary supplements, including dietary foods for special purposes) grew by around 4% by value.
Despite a record number of flu cases (5 million), an impressive number of dietary supplements notifications
(11,200) and the highest number of OTC drugs authorised for marketing by URPL since 2012 (over 100),
the market change was much lower than a year earlier. Forecasts till 2023 are available in PMR products.
Please contact us at +48 12 340 51 30 Monday - Friday 8am - 5pm CET.
Get instant access to PMR's up-to-date datasets and reports.